Literature DB >> 26184954

[Myositides: What is the current situation?].

K M Rösler1, O Scheidegger.   

Abstract

This article gives a review of the classification, diagnostic procedures and treatment of idiopathic inflammatory myopathies from a neurological point of view. The myositis syndromes can be subdivided into four groups, polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM) and necrotizing myopathy (NM), which substantially differ clinically and pathophysiologically. Myositis may also occur in association with cancer or autoimmune systemic diseases (overlap syndrome). Diagnosis of inflammatory myopathies is based on clinical symptoms, determination of creatine phosphokinase and acute phase parameters in blood (e.g. C-reactive protein and erythrocyte sedimentation rate), electromyography results and findings of magnetic resonance imaging (MRI) in muscle. A muscle biopsy is mandatory to confirm the diagnosis. High quality randomized controlled trials of treatment regimens for inflammatory myopathies are sparse; however, empirical experience indicates a clear effectiveness of immunosuppressive treatment of PM, DM and NM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26184954     DOI: 10.1007/s00393-014-1547-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  64 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features.

Authors:  Stefen Brady; Waney Squier; David Hilton-Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-07-16       Impact factor: 10.154

3.  Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.

Authors:  Marion Couderc; Jacques-Eric Gottenberg; Xavier Mariette; Eric Hachulla; Jean Sibilia; Olivier Fain; Arnaud Hot; Maxime Dougados; Liana Euller-Ziegler; Pierre Bourgeois; Claire Larroche; Anne Tournadre; Zahir Amoura; Bernard Mazières; Philippe Arlet; Michel De Bandt; Thierry Schaeverbeke; Martin Soubrier
Journal:  Rheumatology (Oxford)       Date:  2011-10-22       Impact factor: 7.580

4.  Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.

Authors:  Patrick Cherin; S Pelletier; A Teixeira; P Laforet; T Genereau; A Simon; T Maisonobe; B Eymard; S Herson
Journal:  Arthritis Rheum       Date:  2002-02

Review 5.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

Review 6.  Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Authors:  Patrick A Gordon; John B Winer; Jessica E Hoogendijk; Ernest H S Choy
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

7.  Simultaneous T₂ and lipid quantitation using IDEAL-CPMG.

Authors:  Robert L Janiczek; Giulio Gambarota; Christopher D J Sinclair; Tarek A Yousry; John S Thornton; Xavier Golay; Rexford D Newbould
Journal:  Magn Reson Med       Date:  2011-05-20       Impact factor: 4.668

Review 8.  Evaluation and treatment of inflammatory myopathies.

Authors:  A A Amato; R J Barohn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-10       Impact factor: 10.154

9.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.

Authors:  Nizar Chahin; Andrew G Engel
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

10.  Long-duration polyphasic motor unit potentials in myopathies: a quantitative study with pathological correlation.

Authors:  A Uncini; D J Lange; R E Lovelace; M Solomon; A P Hays
Journal:  Muscle Nerve       Date:  1990-03       Impact factor: 3.217

View more
  1 in total

Review 1.  [Paraneoplasms of the skin].

Authors:  C Gießen-Jung; A Wollenberg; M Reinholz
Journal:  Internist (Berl)       Date:  2018-02       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.